Tango Therapeutics

Tango Therapeutics is a clinical-stage biotechnology company that discovers and develops targeted cancer therapies using a CRISPR-based functional genomics platform to find new drug targets. It focuses on synthetic lethality and precision oncology. Its mission is to deliver new medicines to cancer patients. Its lead programs are PRMT5 inhibitors for MTAP-deleted cancers, including vopimetostat (TNG462), and a USP1 inhibitor (TNG348).